Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Unicycive Therapeutics announced that CEO Shalabh Gupta will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company is a clinical-stage biotechnology firm focused on kidney diseases, with lead asset oxylanthanum carbonate and second asset UNI-494, which holds Orphan Drug Designation.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.